

Yan Gong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6328179/publications.pdf>

Version: 2024-02-01

92
papers

2,045
citations

279487

23
h-index

288905

40
g-index

92
all docs

92
docs citations

92
times ranked

3499
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiotoxicity as an adverse effect of immunomodulatory drugs and proteasome inhibitors in multiple myeloma: A network meta-analysis of randomized clinical trials. <i>Hematological Oncology</i> , 2022, 40, 233-242.	0.8	22
2	Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 146-155.	2.3	7
3	A Randomized, Cross-over Trial of Metoprolol Succinate Formulations to Evaluate PK and PD Endpoints for Therapeutic Equivalence. <i>Clinical and Translational Science</i> , 2022, , .	1.5	1
4	Analysis of Biological Aging and Risks of All-Cause and Cardiovascular Disease-Specific Death in Cancer Survivors. <i>JAMA Network Open</i> , 2022, 5, e2218183.	2.8	7
5	Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity. <i>Clinical and Translational Science</i> , 2021, 14, 36-46.	1.5	13
6	Optimizing Precision of Hypertension Care to Maximize Blood Pressure Control: A Pilot Study Utilizing a Smartphone App to Incorporate Plasma Renin Activity Testing. <i>Clinical and Translational Science</i> , 2021, 14, 617-624.	1.5	1
7	Implications of Polymorphisms in the BCKDK and GATA4 Gene Regions on Stable Warfarin Dose in African Americans. <i>Clinical and Translational Science</i> , 2021, 14, 492-496.	1.5	0
8	Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 705-715.	2.3	25
9	Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. <i>Cardio-Oncology</i> , 2021, 7, 10.	0.8	12
10	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021, 42, 1742-1756.	1.0	63
11	Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 645122.	1.1	9
12	Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease. <i>JAMA Network Open</i> , 2021, 4, e218418.	2.8	19
13	Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 723-732.	2.3	6
14	Genome-wide Association Study Identified Chromosome 8 Locus Associated with Medication-Related Osteonecrosis of the Jaw. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1558-1569.	2.3	8
15	Pharmacogenetic predictors of nevirapine pharmacokinetics in Ghanaian children living with HIV with or without TB coinfection. <i>Infection, Genetics and Evolution</i> , 2021, 92, 104856.	1.0	4
16	Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients. <i>Metabolites</i> , 2021, 11, 645.	1.3	7
17	A hybrid implementation-effectiveness randomized trial of CYP2D6-guided postoperative pain management. <i>Genetics in Medicine</i> , 2021, 23, 621-628.	1.1	17
18	A target lipidomics approach to investigate the acute inflammatory irritation induced by indolealkylamines from Chansu water fraction in rats. <i>Chinese Journal of Natural Medicines</i> , 2021, 19, 856-867.	0.7	0

#	ARTICLE	IF	CITATIONS
19	Evaluating an interactive teaching approach with personal genotyping to provide pharmacy students with a knowledge base for clinical pharmacogenetics. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 343-351.	0.5	1
20	Association of <i>P2RX7</i> functional variants with localized aggressive periodontitis. <i>Journal of Periodontal Research</i> , 2020, 55, 32-40.	1.4	11
21	Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence. <i>American Journal of Hypertension</i> , 2020, 33, e2-e2.	1.0	0
22	Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting. <i>American Journal of Hypertension</i> , 2020, 33, 316-324.	1.0	5
23	Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The International Verapamil SR-Trandolapril Study (INVEST). <i>Journal of Women's Health</i> , 2020, 29, 158-166.	1.5	1
24	Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across <i>CYP2D6</i> Genotype-Derived Activity Scores. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 678-685.	1.3	13
25	Attended vs unattended systolic blood pressure measurement: A randomized comparison in patients with cardiovascular disease. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1987-1992.	1.0	8
26	Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events – An analysis from INVEST†. <i>International Journal of Cardiology: Hypertension</i> , 2020, 7, 100052.	2.2	1
27	Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. <i>Pharmacogenomics Journal</i> , 2020, 20, 724-735.	0.9	25
28	SIRT1 Gene SNP rs932658 Is Associated With Medication-Related Osteonecrosis of the Jaw. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 347-356.	3.1	14
29	Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. <i>PLoS ONE</i> , 2019, 14, e0221957.	1.1	7
30	CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. <i>Genetics in Medicine</i> , 2019, 21, 1842-1850.	1.1	96
31	β_2 -Adrenergic Receptor Gene Affects the Heart Rate Response of β_1 -Blockers: Evidence From 3 Clinical Studies. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1462-1470.	1.0	9
32	Pharmacogenomics of osteonecrosis of the jaw. <i>Bone</i> , 2019, 124, 75-82.	1.4	23
33	Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. <i>American Journal of Hypertension</i> , 2019, 32, 668-675.	1.0	9
34	Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 131, 93-98.	1.9	13
35	Brief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 421-425.	0.9	5
36	MADEx: A System for Detecting Medications, Adverse Drug Events, and Their Relations from Clinical Notes. <i>Drug Safety</i> , 2019, 42, 123-133.	1.4	35

#	ARTICLE	IF	CITATIONS
37	Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease. <i>Journal of Clinical Hypertension</i> , 2019, 21, 91-101.	1.0	14
38	Genome-wide association analysis of common genetic variants of resistant hypertension. <i>Pharmacogenomics Journal</i> , 2019, 19, 295-304.	0.9	16
39	Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β -Blockers. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	18
40	Intensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with high-normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database. <i>Journal of Clinical Hypertension</i> , 2018, 20, 620-624.	1.0	5
41	Conflicting meal recommendations for oral oncology drugs: pose risks to patient care?. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 833-842.	0.8	3
42	Design and rationale for the precision medicine guided treatment for cancer pain pragmatic clinical trial. <i>Contemporary Clinical Trials</i> , 2018, 68, 7-13.	0.8	16
43	Genome Wide Association Study Identifies the <i>HMGC2</i> Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	13
44	Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 181-191.	1.1	213
45	Factors Affecting the Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer. <i>JAMA Oncology</i> , 2018, 4, 264.	3.4	2
46	Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors. <i>Cardiovascular Toxicology</i> , 2018, 18, 184-191.	1.1	10
47	Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease. <i>Journal of Hypertension</i> , 2018, 36, 419-427.	0.3	5
48	<i>SIRT1/HERC4</i> Locus Associated With Bisphosphonate-Induced Osteonecrosis of the Jaw: An Exome-Wide Association Analysis. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 91-98.	3.1	31
49	Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. <i>BMC Medical Genomics</i> , 2018, 11, 55.	0.7	6
50	Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients: A retrospective case control study. <i>Special Care in Dentistry</i> , 2018, 38, 356-361.	0.4	11
51	Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. <i>American Journal of Medicine</i> , 2018, 131, 1463-1472.e7.	0.6	16
52	Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 534-543.	5.5	84
53	Pharmacogenetic Associations of β_1 -Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). <i>Stroke</i> , 2017, 48, 1337-1343.	1.0	24
54	Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 1301-1308.	1.0	11

#	ARTICLE	IF	CITATIONS
55	Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. <i>Scientific Reports</i> , 2017, 7, 16068.	1.6	5
56	Genetic Variants Associated With Uncontrolled Blood Pressure on β -Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil SR Trandolapril Study) Trials. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	15
57	Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide. <i>Hypertension</i> , 2017, 69, 51-59.	1.3	34
58	Long-term clinical response to treatment and maintenance of localized aggressive periodontitis: a cohort study. <i>Journal of Clinical Periodontology</i> , 2017, 44, 158-168.	2.3	28
59	Colorectal cancer stages transcriptome analysis. <i>PLoS ONE</i> , 2017, 12, e0188697.	1.1	29
60	A Genetic Response Score for Hydrochlorothiazide Use. <i>Hypertension</i> , 2016, 68, 621-629.	1.3	21
61	Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). <i>Journal of Bone and Mineral Research</i> , 2016, 31, 336-340.	3.1	79
62	Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. <i>Metabolomics</i> , 2016, 12, 1.	1.4	10
63	Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease. <i>Hypertension</i> , 2016, 68, 1110-1114.	1.3	25
64	Metabolomics method based on ultra high performance liquid chromatography with time-of-flight mass spectrometry to analyze toxins in fresh and dried toad venom. <i>Journal of Separation Science</i> , 2016, 39, 4681-4687.	1.3	6
65	Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol. <i>Metabolomics</i> , 2016, 12, 1.	1.4	14
66	Long-term variability of exhaled nitric oxide measurements. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 147-148.e1.	2.0	0
67	Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. <i>Journal of Women's Health</i> , 2016, 25, 996-1003.	1.5	14
68	Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β -Blockers in Hypertensive African Americans. <i>Hypertension</i> , 2016, 67, 556-563.	1.3	41
69	CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. <i>Journal of Neurosurgery</i> , 2016, 124, 1746-1751.	0.9	24
70	PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. <i>Journal of Hypertension</i> , 2015, 33, 2278-2285.	0.3	38
71	Effects of Verapamil SR and Atenolol on 24-Hour Blood Pressure and Heart Rate in Hypertension Patients with Coronary Artery Disease: An International Verapamil SR-Trandolapril Ambulatory Monitoring Substudy. <i>PLoS ONE</i> , 2015, 10, e0122726.	1.1	4
72	Pharmacogenomics of Hypertension: A Genome-Wide, Placebo-Controlled Cross-Over Study, Using Four Classes of Antihypertensive Drugs. <i>Journal of the American Heart Association</i> , 2015, 4, e001521.	1.6	74

#	ARTICLE	IF	CITATIONS
73	<i>CYP2C19</i> Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study. <i>Journal of the American Heart Association</i> , 2015, 4, e001652.	1.6	44
74	Drug induced osteonecrosis of the jaw. <i>Cancer Treatment Reviews</i> , 2015, 41, 455-464.	3.4	75
75	Effect of drying methods on the free and conjugated bufadienolide content in toad venom determined by ultra-performance liquid chromatography-triple quadrupole mass spectrometry coupled with a pattern recognition approach. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 114, 482-487.	1.4	13
76	Impact of Aspirin According to Type of Stable Coronary Artery Disease: Insights from a Large International Cohort. <i>American Journal of Medicine</i> , 2015, 128, 137-143.	0.6	7
77	Large-scale Gene-centric Analysis Identifies Polymorphisms for Resistant Hypertension. <i>Journal of the American Heart Association</i> , 2014, 3, e001398.	1.6	32
78	Hypertension Pharmacogenomics. , 2014, , 747-778.		0
79	<i>PROX1</i> Gene Variant is Associated with Fasting Glucose Change After Antihypertensive Treatment. <i>Pharmacotherapy</i> , 2014, 34, 123-130.	1.2	9
80	Alteration in fasting glucose after prolonged treatment with a thiazide diuretic. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 363-369.	1.1	3
81	Baseline predictors of central aortic blood pressure: A PEAR substudy. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 152-158.	2.3	10
82	2014 Eighth Joint National Committee Panel Recommendation for Blood Pressure Targets Revisited. <i>Journal of the American College of Cardiology</i> , 2014, 64, 784-793.	1.2	67
83	Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 697-705.	0.7	12
84	Hypertension Susceptibility Loci and Blood Pressure Response to Antihypertensives. <i>Circulation: Cardiovascular Genetics</i> , 2012, 5, 686-691.	5.1	55
85	Blood Pressure Responses and Metabolic Effects of Hydrochlorothiazide and Atenolol. <i>American Journal of Hypertension</i> , 2012, 25, 359-365.	1.0	12
86	Chromosome 9p21 Haplotypes and Prognosis in White and Black Patients With Coronary Artery Disease. <i>Circulation: Cardiovascular Genetics</i> , 2011, 4, 169-178.	5.1	29
87	Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated With Antihypertensive Medications. <i>Hypertension</i> , 2010, 55, 61-68.	1.3	60
88	Systolic Blood Pressure and Subjective Well-being in Patients with Coronary Artery Disease. <i>Clinical Cardiology</i> , 2009, 32, 627-632.	0.7	15
89	Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. <i>American Heart Journal</i> , 2009, 157, 442-449.	1.2	119
90	Single nucleotide polymorphism discovery and haplotype analysis of Ca ²⁺ -dependent K ⁺ channel beta-1 subunit. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 267-275.	0.7	5

#	ARTICLE	IF	CITATIONS
91	Memory-related deficits following selective hippocampal expression of Swedish mutation amyloid precursor protein in the rat. <i>Experimental Neurology</i> , 2006, 200, 371-377.	2.0	11
92	Recombinant adeno-associated virus serotype 2 effectively transduces primary rat brain astrocytes and microglia. <i>Brain Research Protocols</i> , 2004, 14, 18-24.	1.7	11